New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 10, 2014
08:16 EDTBCRFDA posts 12-month results of C.R. Bard Levant 2 trial
The FDA posted on its website briefing documents ahead of a circulatory system devices panel meeting scheduled for June 12, where an advisory committee will review C.R. Bard's Lutonix drug-coated balloon PTA catheter. Among the documents posted was C.R. Bard's executive summary, which contains the 12-month results of its pivotal Levant 2 trial. "Freedom from TLR was numerically favorable for the Lutonix DCB group, but no statistical difference between arms in Freedom from TLR rates was observed," the company stated in the summary. Reference Link
News For BCR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 20, 2015
06:32 EDTBCRC.R. Bard upgraded to Neutral from Underweight at JPMorgan
JPMorgan upgraded C.R. Bard to Neutral on expectations drug-coated balloons growth in the U.S. is likely to exceed consensus expectations. The firm raised its price target for shares to $178 from $162.
January 13, 2015
17:13 EDTBCRC.R. Bard wins favorable patent ruling over W.L. Gore & Associates
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use